Literature DB >> 6655470

Deficient natural killer cell (NK) activity and macrophage functioning in schizophrenic patients.

L E DeLisi, J R Ortaldo, A E Maluish, R J Wyatt.   

Abstract

The cytotoxic potential of mononuclear blood cells from 27 chronic schizophrenic patients was evaluated using quantitative measures of natural killer cell activity and macrophage inhibition of tumor cell growth. 44% of the patients had some evidence of deficient in vitro mononuclear cell function which was not correlated with a qualitative or quantitative alteration in the histologic appearance of these peripheral blood cells.

Entities:  

Mesh:

Year:  1983        PMID: 6655470     DOI: 10.1007/BF01249128

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  25 in total

1.  [Antinuclear antibodies and lupus due to phenothiazines in 600 hospitalized patients].

Authors:  M Gallien; J P Schnetzler; J Morin
Journal:  Ann Med Psychol (Paris)       Date:  1975-02       Impact factor: 0.380

2.  Nuclear changes in the white blood cells of patients with schizophrenic reaction. A preliminary report.

Authors:  H VANDER KAMP
Journal:  J Neuropsychiatr       Date:  1962 Sep-Oct

3.  Schizophrenia and malignant neoplasms in a North Swedish population.

Authors:  K Modrzewska; J A Böök
Journal:  Lancet       Date:  1979-02-03       Impact factor: 79.321

4.  An analysis of lymphocyte subpopulations in schizophrenic patients.

Authors:  L E DeLisi; S Goodman; L M Neckers; R J Wyatt
Journal:  Biol Psychiatry       Date:  1982-09       Impact factor: 13.382

5.  Quantitative determination of immunoglobulins in CSF and plasma of chronic schizophrenic patients.

Authors:  L E Delisi; D R Weinberger; S Potkin; L M Neckers; D J Shiling; R J Wyatt
Journal:  Br J Psychiatry       Date:  1981-12       Impact factor: 9.319

6.  Lymphocyte subpopulations in peripheral blood from schizophrenic patients.

Authors:  H Nyland; A Naess; H Lunde
Journal:  Acta Psychiatr Scand       Date:  1980-04       Impact factor: 6.392

7.  Antinuclear antibodies in psychiatric illness: their relationship to diagnosis and drug treatment.

Authors:  E C Johnstone; K Whaley
Journal:  Br Med J       Date:  1975-06-28

Review 8.  Natural killer cells: their roles in defenses against disease.

Authors:  R B Herberman; J R Ortaldo
Journal:  Science       Date:  1981-10-02       Impact factor: 47.728

9.  Characteristics of human large granular lymphocytes and relationship to natural killer and K cells.

Authors:  T Timonen; J R Ortaldo; R B Herberman
Journal:  J Exp Med       Date:  1981-03-01       Impact factor: 14.307

10.  Low natural-killer-cell activity in familial melanoma patients and their relatives.

Authors:  P Hersey; A Edwards; M Honeyman; W H McCarthy
Journal:  Br J Cancer       Date:  1979-07       Impact factor: 7.640

View more
  5 in total

1.  Could natural killer cell activity be linked to the reduced incidence of cancer in schizophrenic patients?

Authors:  J S McDaniel
Journal:  J Epidemiol Community Health       Date:  1990-06       Impact factor: 3.710

Review 2.  The Role of the Immune System in Autism Spectrum Disorder.

Authors:  Amory Meltzer; Judy Van de Water
Journal:  Neuropsychopharmacology       Date:  2016-08-18       Impact factor: 7.853

Review 3.  Roles of inflammation in intrinsic pathophysiology and antipsychotic drug-induced metabolic disturbances of schizophrenia.

Authors:  Tyler R Prestwood; Roshanak Asgariroozbehani; Sally Wu; Sri Mahavir Agarwal; Ryan W Logan; Jacob S Ballon; Margaret K Hahn; Zachary Freyberg
Journal:  Behav Brain Res       Date:  2021-01-14       Impact factor: 3.332

Review 4.  Multiple Sclerosis and Schizophrenia.

Authors:  Borros M Arneth
Journal:  Int J Mol Sci       Date:  2017-08-12       Impact factor: 5.923

5.  Gut permeability and its clinical relevance in schizophrenia.

Authors:  Ikki Ishida; Jun Ogura; Emiko Aizawa; Miho Ota; Shinsuke Hidese; Yukihito Yomogida; Junko Matsuo; Sumiko Yoshida; Hiroshi Kunugi
Journal:  Neuropsychopharmacol Rep       Date:  2022-01-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.